DelfaGLP-1 Atlas

Lead sponsor

The University of Texas Health Science Center, Houston

10 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.

10

Trials led

5

Active

1,009

Total enrollment

5

Sites

Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.

Portfolio

How this sponsor's trials break down

Trials by phase

Phase 1/2
2
Phase 2
4
Phase 4
3
Not applicable
1

Trials by status

Recruiting
5
Completed
5

Trials led

Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With PrediabetesBMI ≥30Ph 4Recruiting300
Semaglutide for Post-Smoking Cessation Weight ManagementBMI ≥30Ph 2Recruiting197
Exenatide for Smoking Cessation and Prevention of Weight GainBMI ≥25Ph 2Completed140
Protective Benefits of a Clear Liquid Diet on Residual Gastric Content in Patients Taking Glucagon Like Peptide-1 Receptor (GLP-1 RA) Agonist Prior to Anesthesia—not applicableRecruiting136
Exenatide Once Weekly for Smoking CessationBMI ≥25Ph 1/2Completed84
Repurposing Semaglutide for the Treatment of Cocaine Use DisorderBMI ≥25Ph 2Recruiting75
REINFORCEBMI ≥30Ph 2Recruiting30
GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic ResponseBMI ≤35Ph 4Completed23
Effects of Antidiabetic Medications on the Postprandial State in PrediabetesBMI 30-35Ph 4Completed21
Exenatide for Treating Cocaine Use Disorder—Ph 1/2Completed3